Press launch MHRA approves GLP –one receptor agonist semaglutide to cut back hazard of serious heart difficulties in obese or overweight Grownups Semaglutide is the main fat reduction drug authorized in the united kingdom to be a preventative cure for people with founded cardiovascular diseaseThere are a selection of scaled-down and online-only p